STOCK TITAN

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management

Nevro Corp. (NYSE: NVRO) has announced the granting of inducement restricted stock unit awards to 20 new non-executive employees. The awards, approved by the Compensation Committee on December 7, 2024, cover 26,000 shares of Nevro's common stock. These grants were made under the Nevro Corp. 2023 Inducement Award Plan and will vest over a three-year period, contingent on continued employment. The awards were granted in accordance with NYSE Listed Company Manual Rule 303A.08 as material inducements to employment.

Nevro Corp. (NYSE: NVRO) ha annunciato l'assegnazione di premi di unità azionarie contingentate come incentivo a 20 nuovi dipendenti non esecutivi. I premi, approvati dalla Commissione per la Retribuzione il 7 dicembre 2024, coprono 26.000 azioni ordinarie di Nevro. Questi conferimenti sono stati effettuati ai sensi del Piano di Assegnazione degli Incentivi Nevro Corp. 2023 e si matureranno in un periodo di tre anni, a condizione che il dipendente continui a lavorare. I premi sono stati concessi in conformità con la Regola 303A.08 del Manuale delle Aziende Elencate della NYSE come incentivi materiali all'assunzione.

Nevro Corp. (NYSE: NVRO) ha anunciado la concesión de premios de unidades de acciones restringidas por incentivo a 20 nuevos empleados no ejecutivos. Los premios, aprobados por el Comité de Compensación el 7 de diciembre de 2024, abarcan 26,000 acciones ordinarias de Nevro. Estas concesiones se realizaron bajo el Plan de Premios por Incentivo de Nevro Corp. 2023 y se consolidarán durante un período de tres años, sujeto a la continuación en el empleo. Los premios se otorgaron de acuerdo con la Regla 303A.08 del Manual de Empresas Cotizadas de la NYSE como incentivos materiales para el empleo.

네브로Corp. (NYSE: NVRO)는 20명의 새로운 비상임 직원에게 유도 제한 주식 단위 보상을 제공한다고 발표했습니다. 이 보상은 2024년 12월 7일 보상 위원회에서 승인되었으며, 네브로의 보통주 26,000주를 포함합니다. 이 보상은 네브로Corp. 2023 유도 보상 계획에 따라 이루어졌으며, 계속 고용될 경우 3년 동안 분할됩니다. 이 보상은 NYSE 상장 기업 매뉴얼 규칙 303A.08에 따라 고용에 대한 물질적 유도로 지급되었습니다.

Nevro Corp. (NYSE: NVRO) a annoncé l'octroi de récompenses d'unités d'actions restreintes d'incitation à 20 nouveaux employés non exécutifs. Les récompenses, approuvées par le Comité de Rémunération le 7 décembre 2024, couvrent 26 000 actions ordinaires de Nevro. Ces attributions ont été effectuées dans le cadre du Plan d'Attribution d'Incitations Nevro Corp. 2023 et seront acquises sur une période de trois ans, sous réserve de maintenir l'emploi. Les récompenses ont été accordées conformément à la règle 303A.08 du Manuel des Sociétés Cotées de la NYSE comme incitations matérielles à l'emploi.

Nevro Corp. (NYSE: NVRO) hat die Gewährung von Anreizzuteilungen für beschränkte Aktieneinheiten an 20 neue nicht-executive Mitarbeiter bekannt gegeben. Die Auszeichnungen, die am 7. Dezember 2024 vom Vergütungsausschuss genehmigt wurden, betreffen 26.000 Stammaktien von Nevro. Diese Zuteilungen erfolgten im Rahmen des Nevro Corp. 2023 Anreiz-Auszeichnungsplans und werden über einen Zeitraum von drei Jahren unter der Voraussetzung fortgesetzter Beschäftigung fällig. Die Zuteilungen wurden gemäß Regel 303A.08 des Handbuchs für börsennotierte Unternehmen der NYSE als materielle Anreize für die Beschäftigung gewährt.

Positive
  • Stock-based compensation aligns new employee interests with shareholders
  • Three-year vesting period promotes employee retention
Negative
  • Potential dilution of existing shareholders from 26,000 new shares
  • Additional stock-based compensation expense impact on financial statements

REDWOOD CITY, Calif., Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on December 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,000 shares of Nevro's common stock to 20 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date.

Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.

Senza®, Senza II®, Senza Omnia™, and HFX iQ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with Nevrocloud™ insights for enhanced patient and practice management.

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo,  Nevrocloud, RELIEF MULTIPLIED, HFX AdaptivAI, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents. Bluetooth® and the Bluetooth symbol are registered trademarks of their respective owners.

To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.

Investor and Media Contact:

Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com

.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-new-employee-inducement-grants-under-nyse-rule-303a08-302334235.html

SOURCE Nevro Corp.

FAQ

How many shares were granted in Nevro's (NVRO) December 2024 inducement awards?

Nevro granted inducement restricted stock unit awards covering 26,000 shares of common stock to 20 new non-executive employees.

What is the vesting period for Nevro's (NVRO) December 2024 inducement grants?

The inducement awards vest over a three-year period, subject to continued employment with Nevro through each vesting date.

How many employees received Nevro's (NVRO) December 2024 inducement grants?

20 new non-executive employees received inducement restricted stock unit awards.

Under which plan were Nevro's (NVRO) December 2024 inducement awards granted?

The awards were granted under the Nevro Corp. 2023 Inducement Award Plan.

What NYSE rule authorized Nevro's (NVRO) December 2024 inducement grants?

The grants were made in accordance with NYSE Listed Company Manual Rule 303A.08 as material inducements to employment.

NEVRO CORP.

NYSE:NVRO

NVRO Rankings

NVRO Latest News

NVRO Stock Data

140.89M
36.06M
3.69%
103.89%
6.98%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
REDWOOD CITY